Analysts have turned bearish on CanSino Biologics, slashing next year's revenue estimates and predicting losses. Despite downgrades, they still foresee CanSino outpacing the broader industry.
Despite boasting a strong balance sheet, the company's future financial stability is questionable due to the negative free cash outflow of CN¥1.9b over the past 12 months and inconsistencies in free cash flow production.
Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up.$康希諾生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million.$瑞科生物-B(02179.HK)$,$諾誠健華(09969.HK)$and ...
$康希諾生物(06185.HK)$price is up on speculation cansino inhaler ( whole 1st Covid inhaler from china with promising result ) will be approved by china body by end of Q3 2022. it will have great potential revenue once the inhaler version is approved because it is using the same vaccine approved by WHO.
Peter YCS樓主 : 康希諾多瀉點……瀉乾淨點……你這股讓虧這麼多,瀉到 5塊錢吧……